Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trialBruce Cree, Eliezer Katz, Orhan Aktaş et al.|The Lancet|2019Cited by 722
Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosisSergio E. Baranzini, Jorge R. Oksenberg, Joanne Wang et al.|Human Molecular Genetics|2008Cited by 479
Treatment of Neuromyelitis Optica With RituximabAnu Jacob, Bruce Cree, Brian G. Weinshenker et al.|Archives of Neurology|2008Cited by 460
Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trialFred Lublin, Ludwig Kappos, David H. Miller et al.|The Lancet|2016Cited by 449
Mapping Multiple Sclerosis Susceptibility to the HLA-DR Locus in African AmericansJorge R. Oksenberg, Stephen L. Hauser, Lisa F. Barcellos et al.|The American Journal of Human Genetics|2004Cited by 345